AxoGen, Inc. to Participate at the American Association of Oral and Maxillofacial Surgeons 98th Annual Meeting
September 12 2016 - 7:00AM
AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical
solutions for peripheral nerve injuries, today announced its
participation at the American Association of Oral and Maxillofacial
Surgeons 98th Annual Meeting taking place in Las Vegas, Nevada from
September 18-23, 2016.
The meeting will feature an AxoGen supported
lecture and lab session, with additional sessions and poster
presentations regarding the use of AxoGen products. AxoGen’s
full portfolio of nerve assessment and nerve repair products will
be featured at AAOMS Booth 868. AxoGen will also have
clinical leaders in trigeminal nerve repair available at the booth
during the conference. The distal trigeminal nerve is
responsible for sensation in the mouth, tongue and lip, and can be
injured in certain dental procedures such as third molar
extraction, dental implant placement or mandible
reconstruction.
“We are pleased to see the increased level of
scientific discussion about nerve injury and repair at this year’s
AAOMS Annual Meeting,” stated Karen Zaderej, AxoGen’s President and
Chief Executive Officer. “Oral and Maxillofacial injuries are a key
focus for AxoGen and these clinical sessions and poster
presentations, along with our continuing education initiative,
reinforce AxoGen’s products as the preeminent choice for peripheral
nerve repair surgery.”
The nerve related presentations for the AAOMS
Meeting are as follows:
Wednesday, September 21,
2016 |
|
|
From the Microscope to the Patient: What
to Do Next In Lingual and Inferior Alveolar Nerve
Injuries |
|
|
Speakers: Anthony M. Spina, Martin B. Steed,
Michael Miloro, Shahrokh C. Bagheri, John R. Zuniga |
|
|
|
Thursday, September 22,
2016 |
|
|
AxoGen Supported Lecture and Lab: Numb
Lip, Numb Chin, Numb Tongue: What to Do When |
|
|
Speakers: Ramzey Tursun, J. Marshall Green III,
Andre C. Ledoux |
|
|
|
|
|
Outcome of Immediate Allograft
Reconstruction of Long Span Defects of the Inferior Alveolar
Nerve |
|
|
Speakers: David Salomon, Michael Miloro |
|
|
|
Friday, September 23,
2016 |
|
|
Updates in Trigeminal Nerve
Microsurgery |
|
|
Speaker: Vincent B. Ziccardi |
|
|
|
|
|
Immediate Nerve Allograft Reconstruction
with Ablation of Mandible for Benign Pathology |
|
|
Speakers: John R. Zuniga, Fayette C. Williams,
Daniel Petrisor |
|
|
|
|
|
Outcome of Immediate Allograft
Reconstruction of Long Span Defects of the Inferior Alveolar
Nerve |
|
|
Speakers: David Salomon, Michael Miloro |
|
|
|
About AAOMS 2016The mission of
the American Association of Oral and Maxillofacial Surgeons is to
promote, protect and advance oral and maxillofacial surgery to
assure excellence for surgeons and their patients. For more
information on the conference, please visit www.aaoms.org.
About AxoGen AxoGen (AXGN) is a
global leader in innovative surgical solutions for peripheral nerve
injuries. AxoGen’s portfolio of products includes Avance® Nerve
Graft, an off-the-shelf processed human nerve allograft for
bridging severed nerves without the comorbidities associated with a
second surgical site, AxoGuard® Nerve Connector, a porcine
submucosa extracellular matrix ("ECM") coaptation aid for
tensionless repair of severed nerves, and AxoGuard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
injured peripheral nerves and reinforce the nerve reconstruction
while minimizing soft tissue attachments. Along with these core
surgical products, AxoGen also offers AxoTouch™ Two-Point
Discriminator and AcroVal™ Neurosensory & Motor Testing System.
These evaluation and measurement tools assist healthcare
professionals in detecting changes in sensation, assessing return
of sensory, grip and pinch function, evaluating effective treatment
interventions, and providing feedback to patients on nerve
function. The AxoGen portfolio of products is available in the
United States, Canada, the United Kingdom and several European and
international countries.
Cautionary Statements Concerning Forward-Looking
StatementsThis Press Release contains "forward-looking" statements
as defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations or
predictions of future conditions, events or results based on
various assumptions and management's estimates of trends and
economic factors in the markets in which we are active, as well as
our business plans. Words such as "expects", "anticipates",
"intends", "plans", "believes", "seeks", "estimates", "projects",
"forecasts", "continue", "may", "should", "will" variations of such
words and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our growth, our
2016 guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made, and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
386.462.6856
InvestorRelations@AxoGenInc.com
The Trout Group – Investor Relations
Brian Korb
646.378.2923
bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024